Inhalation Therapy Nebulizer Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Inhalation Therapy Nebulizer Market is segmented By Type (Mesh Nebulizer, Pneumatic Nebulizer, Ultrasonic Nebulizer, Jet nebulizers), By Applications (Asthma, COPD, Cystic fibrosis, Other), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Inhalation Therapy Nebulizer Market Overview

The global inhalation therapy nebulizer market reached USD 0.8 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 1.6 billion by 2030. The global inhalation therapy nebulizer market is expected to exhibit a CAGR of 9.8% during the forecast period (2024-2031). Inhalation therapy nebulizers are medical devices used in respiratory care to deliver medication directly to the lungs. They are commonly prescribed for patients with respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other lung disorders.

Nebulizers convert liquid medication into a fine mist or aerosol, allowing patients to inhale the medication through a mask or mouthpiece. This method ensures that the medication reaches the lungs directly, providing targeted treatment. There are various types of nebulizers including jet nebulizers, ultrasonic nebulizers, and mesh nebulizers among others.

Furthermore, the increasing prevalence of respiratory diseases, advancements in nebulizer technology, increased awareness and diagnosis, and government initiatives aimed at improving respiratory healthcare are the factors expected to drive the market over the forecast period.

Inhalation Therapy Nebulizer Market Summary

For more insights - Request Free Sample

Inhalation Therapy Nebulizer Market Dynamics

Market Players Signing Agreements for Discounted Home Care Nebulizers to Propel Global Inhalation Therapy Nebulizer Market Growth

On May 25, 2022, AstraZeneca and Rossmax collaborated to make nebulizers more affordable for home care in Iran and Tunisia. AstraZeneca has set up isolated respiratory emergency rooms in hospitals in both countries. The agreement between AstraZeneca and Rossmax aims to assist patients who require nebulization therapy at home by offering discounted prices on Rossmax's NE100 home nebulizer. 

The program will last for three years and includes free delivery of the nebulizers to patients. To participate, patients can either get a referral from their doctor or contact a hotline. They will receive discount vouchers and educational materials about asthma care. Additionally, Rossmax will provide free nebulizers to hospitals where AstraZeneca has installed them.

Increasing Clinical Trials in Inhalation Therapy Nebulizer for Asthma is Expected to Drive Global Inhalation Therapy Nebulizer Market Growth

In 2021, the Centre Hospitalier Intercommunal Creteil conducted an interventional Phase 3 study aimed at comparing the effectiveness and safety of Budesonide/Formoterol Turbuhaler versus Terbutaline Nebulization as a reliever therapy in children with asthma who visited the emergency room for moderate exacerbation. The study, listed on ClinicalTrials.gov, is expected to be completed by February 2024.

The purpose of the study is to assess and compare the two treatment options for children with asthma experiencing a moderate exacerbation. Budesonide/formoterol turbuhaler and terbutaline nebulization are both commonly used as reliever therapies in asthma management. The researchers aim to evaluate which treatment is more effective and safe in relieving symptoms and improving respiratory function in children during an asthma exacerbation.

By conducting an interventional study, the researchers will actively administer the treatments to the participating children and closely monitor their responses. They will assess various factors such as symptom relief, improvement in lung function, adverse events, and the need for additional medication or hospitalization. The study's completion date is estimated to be in February 2024, at which point the researchers will analyze the data collected and draw conclusions regarding the comparative efficacy and safety of the two treatment options.

This study is significant as it contributes to the existing knowledge on asthma management in children, particularly during exacerbations. The findings may help healthcare professionals make informed decisions when selecting appropriate reliever therapies for children with asthma presenting at the emergency room with moderate exacerbations. Thus, from the above factors, the market is expected to drive over the forecast period.

Nebulizers can be expensive, especially for individuals without insurance coverage or in regions with limited healthcare resources. The cost of purchasing the device and ongoing maintenance expenses, such as medication refills and replacement parts, may pose a financial challenge for some patients and healthcare systems.

Disadvantages of Ultrasonic Nebulizers are Expected to Hamper Global Inhalation Therapy Nebulizer Market Growth

Ultrasonic nebulizers have many limitations compared to jet nebulizers. For instance, they have large residual volumes, an inability to aerosolize viscous solutions and degradation of heat-sensitive materials. Therefore, they should not be used with suspensions and proteins. Thus, owing to the above factors, the market is expected to hamper over the forecast period.

Inhalation Therapy Nebulizer Market Segment Analysis

The global inhalation therapy nebulizer market is segmented based on type, application, distribution channel, and region.

Owing to the Increasing in Adoption, Portability, Convenience, and Ease of Use, the Mesh Nebulizer Type Segment Accounted for Approximately 25.3% of the Inhalation Therapy Nebulizer Market Share 

Mesh nebulizers have experienced a significant increase in adoption owing to their notable benefits in terms of portability, efficiency, and user-friendliness. These nebulizers employ a vibrating mesh or plate that contains tiny openings to generate an aerosol mist for medication delivery.

One of their key advantages is their compact size, making them easy to carry and transport. Additionally, mesh nebulizers are lightweight, further enhancing their portability and convenience for patients who require frequent or on-the-go medication administration.

The vibrating mesh technology employed in these nebulizers ensures efficient aerosol generation, resulting in effective medication delivery to the respiratory system. The fine mesh with small holes enables the production of a consistent and fine mist, increasing the likelihood of medication reaching the targeted areas in the lungs. This efficiency contributes to improved treatment outcomes and patient satisfaction.

In addition to their portability and efficiency, mesh nebulizers are recognized for their quiet operation. The vibrating mesh technology operates silently, minimizing any noise disturbance during the treatment process. This feature is particularly valuable for patients who may be sensitive to noise or prefer a peaceful and discreet experience.

Likewise, the advantages offered by mesh nebulizers have made them a preferred choice for individuals requiring frequent or on-the-go medication administration. These may include individuals with chronic respiratory conditions such as asthma or COPD, who need regular and convenient access to their prescribed medications. The portability, efficiency, and quiet operation of mesh nebulizers contribute to improved medication compliance and patient satisfaction.

Thus, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period. 

Source: DataM Intelligence Analysis (2023)

Global Inhalation Therapy Nebulizer Market Geographical Share

North America Accounted for Approximately 38.4% of the Market Share in 2022, Owing to the Increasing Prevalence of Respiratory Disorders and the Development of Novel Compact Nebulizers

According to the Centers for Disease Control and Prevention Report 2022, Chronic lower respiratory disease, specifically chronic obstructive pulmonary disease (COPD), ranked as the sixth leading cause of death in the United States in 2020. Over 15 million individuals in the United States are impacted by COPD. The disease claims the lives of over 150,000 Americans annually, equivalent to one death occurring every four minutes.

While smoking is the primary contributor, it is noteworthy that one out of every four individuals with COPD has never smoked. Additionally, COPD can be caused by factors such as secondhand smoke exposure at home, occupational fumes, and genetic predisposition. Common symptoms include a persistent cough, excessive production of phlegm, shortness of breath, and wheezing. Detecting COPD early and initiating appropriate treatment can potentially alter the progression of the disease. 

Lung function tests can assess respiratory function and identify COPD in individuals at risk. Managing COPD requires a comprehensive evaluation by a healthcare professional, along with measures to avoid tobacco smoke and minimize exposure to air pollutants in both the home and workplace. Medications may be prescribed to alleviate symptoms.

Therefore, due to the increasing prevalence of respiratory disorders, there is a rise in the demand for inhalation therapy nebulizers in the region. Thus, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

Source: DataM Intelligence Analysis (2023)

Inhalation Therapy Nebulizer Market Key Players

The major global players in the market include Rossmax International Ltd,Boehringer Ingelheim GmbH, OMRON Corporation, Koninklijke Philips N.V., PARI Pharma, BD, Medline Industries, Inc., Briggs Healthcare, GF Health Products, Inc., and Drive DeVilbiss International among others.

Russia Ukraine Conflict Analysis

The Russian-Ukraine war has had several impacts on various sectors, including the medical industry. The conflict may lead to disruptions in the supply chains of medical devices, including nebulizers. Ukraine is known for its manufacturing capabilities, and if the conflict affects production facilities or transportation routes, it could result in a shortage of nebulizers in the market.

During times of conflict and unrest, there is often an increase in respiratory illnesses due to various factors such as displacement, stress, poor living conditions, and exposure to environmental pollutants. This increased demand for respiratory treatments may lead to a surge in the need for nebulizers as an inhalation therapy option.

The war may place a strain on the healthcare infrastructure in affected areas, leading to a shortage of medical supplies, including nebulizers. The focus of resources might shift towards addressing immediate emergency needs, potentially impacting the availability and distribution of nebulizers.

International sanctions and trade restrictions imposed during the conflict could impact the import and export of medical devices. This could affect the availability of nebulizers in both Ukraine and Russia, as well as other countries involved in the conflict.

Key Developments

• On March 25, 2021, PARI Pharma obtained authorization in Japan for the Lamira Nebulizer System, designed specifically for delivering Insmed's ARIKAYCE (amikacin liposome inhalation suspension). The Lamira Nebulizer System features the eFlow Technology nebulizer, which has been optimized for administering ARIKAYCE. This drug-specific nebulizer system includes a customized medication reservoir capable of holding a complete 8.4ml dose, an aerosol head tailored for aerosolizing ARIKAYCE, and a valved aerosol chamber.
• On May 6, 2021, Vectura Group plc, a leading inhalation Contract Development and Manufacturing Organization (CDMO), and Inspira Pharmaceuticals Limited, a newly established UK-based company specializing in the development of therapies for respiratory and infectious diseases, announced a partnership to create an inhaled formulation of Inspira's primary drug candidate for treating COVID-19.

Inspira's research primarily revolves around its proprietary IPX formulations, which are derived from processed and purified extracts obtained from a plant source. These extracts contain proteolytic enzymes that have demonstrated the ability to rapidly deactivate the SARS-CoV-2 virus in laboratory tests. The IPX technology platform also holds the potential for treating other respiratory infections and addressing biofilms associated with respiratory diseases.

Why Purchase the Report?

• To visualize the global inhalation therapy nebulizer market segmentation based on the type, application, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of inhalation therapy nebulizer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global inhalation therapy nebulizer market report would provide approximately 61 tables, 59 figures, and 195 Pages.